Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses data from a phase II study of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia (Abstract 7506).
Sarah A. Holstein, MD, PhD, of the University of Nebraska Medical Center, discusses top myeloma abstracts from the ASCO20 Virtual Scientific Program: the ENDURANCE trial on c...
Douglas B. Johnson, MD, of Vanderbilt University Medical Center, discusses three important melanoma abstracts: the need for more than two doses of nivolumab plus ipilimumab i...
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve...
Howard A. Burris III, MD, FACP, FASCO, Immediate Past President of ASCO and current Society Board Chair, talks about how the meeting went, with its record-breaking attendance...
Tingyan Shi, MD, PhD, of Zhongshan Hospital, Fudan University, discusses study results that showed secondary cytoreductive surgery in selected patients extended progression-f...